CICCIA, Francesco
 Distribuzione geografica
Continente #
EU - Europa 12.698
NA - Nord America 7.291
AS - Asia 6.864
SA - Sud America 1.514
Continente sconosciuto - Info sul continente non disponibili 586
AF - Africa 114
OC - Oceania 5
Totale 29.072
Nazione #
RU - Federazione Russa 8.968
US - Stati Uniti d'America 7.027
SG - Singapore 2.390
IE - Irlanda 1.308
CN - Cina 1.254
BR - Brasile 1.222
VN - Vietnam 1.174
HK - Hong Kong 1.095
IT - Italia 1.032
GB - Regno Unito 453
KR - Corea 352
DE - Germania 298
IN - India 186
GR - Grecia 174
AR - Argentina 112
CA - Canada 107
FR - Francia 89
JP - Giappone 65
FI - Finlandia 61
BD - Bangladesh 57
EC - Ecuador 54
ID - Indonesia 54
MX - Messico 50
SE - Svezia 47
UA - Ucraina 39
TR - Turchia 37
ZA - Sudafrica 35
CO - Colombia 34
NL - Olanda 32
AT - Austria 30
ES - Italia 30
PL - Polonia 30
IQ - Iraq 25
PK - Pakistan 25
JM - Giamaica 23
PY - Paraguay 21
VE - Venezuela 21
MA - Marocco 19
UZ - Uzbekistan 19
BE - Belgio 18
PE - Perù 17
CH - Svizzera 16
EG - Egitto 15
TH - Thailandia 15
CL - Cile 14
HN - Honduras 13
CZ - Repubblica Ceca 12
GT - Guatemala 12
KE - Kenya 12
CR - Costa Rica 11
DZ - Algeria 11
EE - Estonia 11
AE - Emirati Arabi Uniti 10
KZ - Kazakistan 10
SA - Arabia Saudita 10
TW - Taiwan 9
UY - Uruguay 9
AZ - Azerbaigian 8
BO - Bolivia 8
PH - Filippine 8
PR - Porto Rico 8
JO - Giordania 7
MY - Malesia 7
NI - Nicaragua 7
NP - Nepal 7
RS - Serbia 7
TT - Trinidad e Tobago 7
IL - Israele 6
MD - Moldavia 6
PA - Panama 6
AL - Albania 5
GP - Guadalupe 5
LT - Lituania 5
OM - Oman 5
TN - Tunisia 5
AU - Australia 4
GE - Georgia 4
MK - Macedonia 4
PT - Portogallo 4
BS - Bahamas 3
CI - Costa d'Avorio 3
CW - ???statistics.table.value.countryCode.CW??? 3
GA - Gabon 3
HU - Ungheria 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
LK - Sri Lanka 3
RO - Romania 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
SV - El Salvador 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
BB - Barbados 2
BG - Bulgaria 2
BH - Bahrain 2
BY - Bielorussia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
IR - Iran 2
Totale 28.462
Città #
Moscow 3.132
Dublin 1.306
Santa Clara 1.107
Hong Kong 1.056
Singapore 966
San Jose 743
Ashburn 735
Council Bluffs 645
Jacksonville 405
Ho Chi Minh City 395
Seoul 348
Hanoi 282
Hefei 257
Princeton 233
Beijing 203
Milan 190
Roxbury 187
Chandler 176
Medford 140
Naples 127
Bremen 121
Los Angeles 102
New York 95
São Paulo 91
Bengaluru 90
Da Nang 76
Dallas 75
Miano 67
Rome 67
Des Moines 64
Ann Arbor 51
Boardman 51
Cambridge 50
Munich 46
The Dalles 44
Wilmington 42
Haiphong 41
North Bergen 41
Jinan 37
Rio de Janeiro 35
Atlanta 34
Nanjing 30
Boston 27
Phoenix 27
Chicago 25
Falkenstein 25
Frankfurt am Main 25
Nuremberg 25
Belo Horizonte 24
Biên Hòa 24
Curitiba 24
Abbeville 23
Brasília 23
Guarulhos 23
Montreal 23
Tokyo 23
Turku 23
Chennai 21
Guayaquil 21
Hải Dương 21
Orem 21
Dearborn 20
Houston 20
Porto Alegre 19
Guangzhou 18
London 18
Palermo 18
Shanghai 18
Bắc Ninh 17
Ninh Bình 17
Tashkent 17
Amsterdam 16
Brooklyn 16
Campinas 16
Hebei 16
Helsinki 16
Johannesburg 16
Kochi 16
Lappeenranta 16
San Francisco 16
Warsaw 16
Buenos Aires 15
Mexico City 15
Shenyang 15
Brussels 14
Caserta 14
Jakarta 14
Vũng Tàu 14
Bangkok 13
Hillsboro 13
Kingston 13
Philadelphia 13
Phủ Lý 13
Salvador 13
Vienna 13
Can Tho 12
Goiânia 12
Thái Bình 12
Bogotá 11
Bến Tre 11
Totale 15.023
Nome #
Ankylosing spondylitis: an autoimmune or autoinflammatory disease? 234
An intense physical rehabilitation programme determines pain relief and improves the global quality of life in patients with fibromyalgia 182
A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis 175
pentoxifylline inhibits vgamma9/vdelta2 t lymphocyte activation of patients with active behçet's disease 172
Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients 158
Adult-onset Still's disease: Evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 157
ABERRANT EXPRESSION OF IL-22RA1 ON HEMATOPOIETIC CELLS AS IMMUNOLOGICALLY SIGNATURE OF PRIMARY SJOGREN’S SYNDROME AND SJOGREN-ASSOCIATED NON-HODGKIN LYMPHOMAS 156
Anifrolumab in Refractory Systemic Lupus Erythematosus: A Real-World, Multicenter Study 151
CD3 immunohistochemistry is helpful in the diagnosis of giant cell arteritis 150
CD8+tissue-resident memory T cells are expanded in primary Sjögren’s disease and can be therapeutically targeted by CD103 blockade 149
Fatigue and Associated Factors in an Immune-Mediated Inflammatory Disease Population: A Cross-Sectional Study 147
Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study 143
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 142
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 142
Expression of HIF1α in intestinal epithelium restricts arthritis inflammation by inhibiting RIPK3-induced cell death machinery 141
Serological Response to BNT162b2 Anti-SARS-CoV-2 Vaccination in Patients with Inflammatory Rheumatic Diseases: Results From the RHEUVAX Cohort 141
Clinical and subclinical atherosclerosis in patients with systemic sclerosis: an observational, multicentre study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) 139
An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab 139
Are Toll-like receptors and decoy receptors involved in the immunopathogenesis of systemic lupus erythematosus and lupus-like syndromes? 138
Gastrointestinal Symptoms Impact Psychosocial Function and Quality of Life in Patients with Rheumatoid Arthritis and Spondyloarthritis: A Cross-Sectional Study 137
Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome 136
Arterial stiffness indexes and serum cytokine levels in seronegative spondyloarthritis: relationships between stiffness markers and metabolic and immunoinflammatory variables 136
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 135
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS) 133
A Th1 but not a Th17 response is present in the gastrointestinal involvement of Behçet's disease 133
Precision medicine in systemic lupus erythematosus 132
The craniovertebral junction in rheumatoid arthritis: State of the art 132
Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease 131
Biomarker panels may be superior over single molecules in prediction of renal flares in systemic lupus erythematosus: an exploratory study 131
Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus 130
Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease 129
Clinical and laboratory features associated with macrophage activation syndrome in Still's disease: data from the international AIDA Network Still's Disease Registry 127
Systemic sclerosis interstitial lung disease: unmet needs and potential solutions 126
Butyrophilin 2a2 (Btn2a2) expression on thymic epithelial cells promotes central T cell tolerance and prevents autoimmune disease 126
Incidence of COVID-19 in an Italian cohort of patients with systemic lupus erythematosus: an observational survey 126
Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region 125
Satisfaction in Social Roles and Physical Function in Immune-mediated Inflammatory Diseases: A Cross-Sectional Study 125
Adult-onset Still's disease with elderly onset: results from a multicentre study 125
A patient-driven registry on Behçet's disease: the AIDA for patients pilot project 124
Development and Implementation of the AIDA International Registry for Patients With Undifferentiated Systemic AutoInflammatory Diseases 124
IL-23 OVEREXPRESSION AS IMMUNOLOGICAL SIGNATURE OF SUBCLINICAL INTESTINAL INFLAMMATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS 124
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome 124
Subclinical gut inflammation in ankylosing spondylitis 123
Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis 123
Gut dysbiosis in Spondyloarthritis: Cause or effect? 121
Activated IL-22 pathway occurs in the muscle tissues of patients with polymyositis or dermatomyositis and is correlated with disease activity 121
ILC3 in Axial Spondyloarthritis: the Gut Angle 121
Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease-Associated spondyloarthritis 121
New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine? 120
H-ferritin and CD68+/H-ferritin+ monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease 120
Distinctive gut microbiomes of ankylosing spondylitis and inflammatory bowel disease patients suggest differing roles in pathogenesis and correlate with disease activity 120
Clinical characteristics of obese patients with adult-onset Still's disease. Data from a large multicentre cohort 118
Gut-derived CD8+ tissue-resident memory T cells are expanded in the peripheral blood and synovia of SpA patients 118
Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort 117
Tocilizumab therapy for unresponsive pulmonary arterial hypertension in a patient with Takayasu arteritis 116
Real-life efficacy of guselkumab in patients with early psoriatic arthritis 116
Derivation and validation of four patient clusters in Still's disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry 115
NKP44+NK cells are expanded and produce high amounts of IL-22 in the salivary glands of Sjrogen syndrome patients 114
Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus 114
Autophagy occurs in lymphocytes infiltrating Sjögren’s syndrome minor salivary glands and correlates with histological severity of salivary gland lesions 114
JAK/STAT Pathway Targeting in Primary Sjögren Syndrome 114
Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus 113
Microbiome Changes in Connective Tissue Diseases and Vasculitis: Focus on Metabolism and Inflammation 112
Interleukin-22 and interleukin-22-producing NKp44+ natural killer cells in subclinical gut inflammation in ankylosing spondylitis 112
Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis 112
Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis 111
Phenotype and functional changes of Vgamma9/Vdelta2 T lymphocytes in Behçet's disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansion, activation and cytotoxicity 111
Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome 110
The gut-enthesis axis and the pathogenesis of Spondyloarthritis 110
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management 110
Gut inflammation in spondyloarthritis 110
Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient 110
Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database 109
Intensive training programme for ultrasound-guided minimally invasive synovial tissue biopsy on knees and wrists in different phases of inflammation 109
Efficacy of canakinumab in patients with Still’s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still’s Disease 109
Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis 109
Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset 109
β-amyloid wall deposit of temporal artery in subjects with spontaneous intracerebral haemorrhage 109
Inflammasome activation in Ankylosing Spondylitis is associated to gut dysbiosis 109
Short-Facelift Approach in Temporal Artery Biopsy: Is It Safe? 108
Correction to: Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study 108
IVIG in APS pregnancy 107
Non-conventional forms of HLA-B27 are expressed in spondyloarthritis joints and gut tissue 107
Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6 106
Intestinal Involvement in Kawasaki Disease 106
New insights into the pathogenesis of giant cell arteritis 106
Parenchymal lung disease in adult onset Still's disease: An emergent marker of disease severity - Characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients 106
Pathogenesis of primary Sjögren's syndrome beyond B lymphocytes 106
Clinical Characteristics of Potential “Difficult-to-treat” Patients with Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort 105
Still's disease continuum from childhood to elderly: data from the international AIDA Network Still's disease registry 105
Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension 105
JAK/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis 105
Impact of smoking habit on adult-onset Still’s disease prognosis, findings from a multicentre observational study 105
Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry 104
The Autoinflammatory Diseases Alliance Registry of monogenic autoinflammatory diseases 104
The Cross-Talk between Microbiome and Metabolome in Rheumatoid Arthritis 104
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS 104
Interstitial lung disease in systemic sclerosis: current and future treatment 104
Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus 104
The bone marrow side of axial spondyloarthritis 103
Totale 12.369
Categoria #
all - tutte 113.338
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 113.338


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022977 0 0 0 24 372 4 37 16 48 28 66 382
2022/20231.724 246 12 26 17 208 59 4 60 1.020 5 43 24
2023/20241.032 35 30 39 55 368 101 27 29 11 7 57 273
2024/20254.236 14 45 9 88 646 518 478 439 537 940 304 218
2025/202616.031 545 866 894 963 1.266 8.304 1.231 582 674 309 212 185
2026/20273.680 182 523 1.419 1.556 0 0 0 0 0 0 0 0
Totale 29.072